

Status: Currently Official on 16-Feb-2025  
 Official Date: Official Prior to 2013  
 Document Type: USP Monographs  
 DocId: GUID-DC723633-7329-4A00-A52E-AFE0DDF2B7DC\_1\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M62520\\_01\\_01](https://doi.org/10.31003/USPNF_M62520_01_01)  
 DOI Ref: qy760

© 2025 USPC  
 Do not distribute

## Pergolide Tablets

» Pergolide Tablets contain an amount of Pergolide Mesylate equivalent to not less than 90.0 percent and not more than 110.0 percent of the labeled amount of pergolide ( $C_{19}H_{26}N_2S$ ).

**Packaging and storage**—Preserve in tight, light-resistant containers.

**USP REFERENCE STANDARDS (11)**—

[USP Pergolide Mesylate RS](#)

[USP Pergolide Sulfoxide RS](#)

(8 $\beta$ )-8-[(Methylsulfinyl)methyl]-6-propyl- $\delta$ -ergoline.

**THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST (201)**—

*Adsorbent*: 0.25-mm layer of binder-free silica gel.

*Test solution*—Transfer a number of Tablets, equivalent to 1 mg of pergolide, to a separator containing 20 mL of methylene chloride and 10 mL of 0.1 N sodium hydroxide. Shake until the Tablets have disintegrated, allow the layers to separate, and drain the methylene chloride layer through a small funnel containing about 1 g of anhydrous sodium sulfate, collecting the filtrate in a suitable stoppered vessel. Wash the sodium sulfate with a few mL of methylene chloride, adding these washes to the filtrate, and evaporate to dryness under a stream of nitrogen. Redissolve the residue in 2 mL of a mixture of methylene chloride and methanol (1:1).

*Standard solution*: 0.65 mg per mL, in a mixture of methylene chloride and methanol (1:1).

*Application volume*: 20  $\mu$ L.

*Developing solvent system*: a mixture of chloroform, methanol, and ethyl acetate (8:1:1). Allow the plate to equilibrate for about 10 minutes in the developing chamber prior to development.

*Procedure*—Proceed as directed in the chapter. Place the plate in a chamber containing iodine vapors, and locate the spots.

**DISSOLUTION (711)**—

*Medium*: simulated gastric fluid TS (without enzymes) containing 20  $\mu$ g of L-cysteine per mL; 500 mL.

*Apparatus 2*: 50 rpm.

*Time*: 30 minutes.

Determine the amount of  $C_{19}H_{26}N_2S$  dissolved by employing the following method.

*Mobile phase*—Prepare a filtered and degassed mixture of acetonitrile, water, and triethylamine, (21:19:0.08). Adjust with phosphoric acid to a pH of 5.0. Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

*Triethylamine phosphate suspension*—Add 1.0 mL of triethylamine to 500 mL of acetonitrile, mix, and adjust with phosphoric acid to a pH of 5.0. A white precipitate will form. Stir continuously during use.

*Resolution solution*—Prepare a solution of [USP Pergolide Mesylate RS](#) and [USP Pergolide Sulfoxide RS](#) containing a known amount of each equivalent to the labeled amount of pergolide in each 500 mL of *Medium*.

*Standard solution*—Transfer about 16 mg of [USP Pergolide Mesylate RS](#), accurately weighed, to a 250-mL volumetric flask, dissolve in 10.0 mL of methanol, dilute with *Medium* to volume, and mix. Dilute this solution quantitatively and stepwise with *Medium* to obtain a solution having a known concentration equivalent to the labeled amount of pergolide in each 500 mL.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a fluorometer set to an excitation wavelength of 224 nm and an emission wavelength of 350 nm and with a 4.6-mm  $\times$  15-cm column that contains base-deactivated packing L10. The flow rate is about 2 mL per minute. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between pergolide sulfoxide and pergolide is not less than 1.0. Chromatograph the *Standard solution*, and record the peak responses as directed for *Procedure*: the relative standard deviation for replicate injections, determined from the pergolide peak, is not more than 2.0%.

*Procedure*—Immediately before injection, pipet 2.0 mL of *Triethylamine phosphate suspension*, continuously stirred, into a suitable container containing 5.0 mL of the solution for injection, and mix to obtain a clear solution. Separately inject equal volumes (about 200  $\mu$ L) of the *Standard solution* and filtered portions of the solutions under test into the chromatograph, record the chromatograms, and measure the areas

for the major peaks. Calculate the amount, in mg, of pergolide ( $C_{19}H_{26}N_2S$ ) dissolved by the formula:

$$500C(314.50/410.60)(r_u/r_s)$$

in which C is the concentration, in  $\mu\text{g}$  per mL, of [USP Pergolide Mesylate RS](#) in the *Standard solution*; 314.50 and 410.60 are the molecular weights of pergolide and pergolide mesylate, respectively; and  $r_u$  and  $r_s$  are the peak areas obtained from the solution under test and the *Standard solution*, respectively.

**Tolerances**—Not less than 75% (Q) of the labeled amount of  $C_{19}H_{26}N_2S$  is dissolved in 30 minutes.

**UNIFORMITY OF DOSAGE UNITS (905)**: meet the requirements.

#### Chromatographic purity—

*Mobile phase, System suitability solution, Standard preparation, and Chromatographic system*—Proceed as directed in the Assay.

*Diluted standard preparation*—Transfer 3.0 mL of the *Standard preparation* to a 50-mL volumetric flask. Dilute with *Mobile phase* to volume, and mix.

*Test preparation*—Use the *Assay preparation*.

*Procedure*—Separately inject equal volumes (about 100  $\mu\text{L}$ ) of the *Diluted standard preparation* and the *Test preparation* into the chromatograph, and measure all of the peak responses. Calculate the percentage of each impurity in the Tablets by the formula:

$$20C(314.50/410.60)(r_i/r_s)$$

in which C is the concentration, in  $\mu\text{g}$  per mL, of [USP Pergolide Mesylate RS](#) in the *Diluted standard preparation*; 314.50 and 410.60 are the molecular weights of pergolide and pergolide mesylate, respectively;  $r_i$  is the peak response of the individual impurity obtained from the *Test preparation*; and  $r_s$  is the peak response of pergolide obtained from the *Diluted standard preparation*: not more than 6.0% of pergolide sulfoxide is found; not more than 0.5% of any individual impurity, excluding pergolide sulfoxide, is found; and not more than 1.0% of total impurities, excluding pergolide sulfoxide, is found.

#### Assay—

*Mobile phase*—Prepare a solution of 0.038 M sodium 1-octanesulfonate containing 0.0077 mg of methionine per mL and 2.45 mL of glacial acetic acid per L. Adjust with 5 N sodium hydroxide to a pH of 4.1. Prepare a filtered and degassed mixture of this solution and acetonitrile (65:35). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

*System suitability solution*—Prepare a solution of [USP Pergolide Mesylate RS](#) and [USP Pergolide Sulfoxide RS](#) in *Mobile phase* having a known concentration of about 6.5  $\mu\text{g}$  per mL of pergolide mesylate and 0.1  $\mu\text{g}$  per mL of pergolide sulfoxide.

*Standard preparation*—Dissolve an accurately weighed quantity of [USP Pergolide Mesylate RS](#) in *Mobile phase*, and dilute quantitatively and stepwise with *Mobile phase* to obtain a solution having a known concentration of about 6.5  $\mu\text{g}$  per mL.

*Assay preparation*—Place 20 whole Tablets into a suitable stoppered container, add *Mobile phase*, shake and sonicate until the Tablets have dissolved, and quantitatively dilute to obtain a solution containing about 5  $\mu\text{g}$  per mL of pergolide.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a fluorometer set to an excitation wavelength of 280 nm and an emission wavelength of 335 nm and with a 4.6-mm  $\times$  7.5-cm column that contains base-deactivated packing L7. The flow rate is about 1.5 mL per minute. The column temperature is maintained at 35°. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*: the resolution, R, between pergolide sulfoxide and pergolide is not less than 12.0; and the relative standard deviation for replicate injections is not more than 2.0%.

*Procedure*—Separately inject equal volumes (about 100  $\mu\text{L}$ ) of the *Standard preparation* and the *Assay preparation* into the chromatograph, and measure the responses for the major peaks. Calculate the quantity, in mg, of pergolide ( $C_{19}H_{26}N_2S$ ) in the portion of Tablets taken by the formula:

$$0.001C(314.50/410.60)(r_u/r_s)$$

in which C is the concentration, in  $\mu\text{g}$  per mL, of [USP Pergolide Mesylate RS](#) in the *Standard preparation*; 314.50 and 410.60 are the molecular weights of pergolide and pergolide mesylate, respectively; and  $r_u$  and  $r_s$  are the peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PERGOLIDE TABLETS	<a href="#">Documentary Standards Support</a>	SM32020 Small Molecules 3

Topic/Question	Contact	Expert Committee
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM32020 Small Molecules 3

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. Information currently unavailable

**Current DocID:** [GUID-DC723633-7329-4A00-A52E-AFE0DDF2B7DC\\_1\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M62520\\_01\\_01](https://doi.org/10.31003/USPNF_M62520_01_01)

**DOI ref:** [qy760](#)

OFFICIAL